Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Trends 2025-2034: Growth, Strategic Insights, and Opportunities Ahead
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Major Innovations Are Driving the Accelerated Growth of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The increasing healthcare expenditure is expected to propel the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market. Rising healthcare expenditure is a result of increased investments in medical infrastructure, demand for advanced treatments, expanded insurance coverage, and efforts to improve healthcare access. This increased spending facilitates better diagnosis and management of CIDP, a rare neurological disorder, through improved treatments and better patient outcomes. In May 2024, the Office for National Statistics in the UK reported a 5.6% increase in healthcare spending from 2022 to 2023. As healthcare expenditure continues to rise, it will drive the growth of the CIDP market by enhancing access to effective therapies.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
#How Does the ProjectedChronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth Compare Over the Forecast Period?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market has seen significant growth, expected to increase from $2.10 billion in 2024 to $2.38 billion in 2025, with a CAGR of 8.4%. Growth has been driven by an aging population, improvements in treatment options, increased awareness and early diagnosis, advancements in immunology and autoimmune research, and a rising prevalence of autoimmune diseases.
The chronic inflammatory demyelinating polyneuropathy (CIDP) market is expected to see steady growth, reaching $3.11 billion in 2029 at a CAGR of 8.1%. Factors contributing to this growth include an aging global population, increasing focus on rare diseases and autoimmune disorders, improved healthcare access, patient advocacy initiatives, and enhanced healthcare infrastructure. Notable trends in this sector include a rising prevalence of CIDP, advancements in treatment options, intensified research and development efforts, the emergence of biosimilar therapies, and the evolution of personalized medicine.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21144
What Are the Most Significant Market Trends Transforming theChronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Leading companies in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are advancing therapies like intravenous immunoglobulin (IVIG) to improve treatment efficacy, patient outcomes, and immune modulation for managing CIDP. IVIG therapy involves infusing concentrated antibodies from healthy donors to help regulate the immune system and reduce inflammation in autoimmune conditions. For example, in January 2024, Takeda Pharmaceutical Company Limited, a Japan-based biopharmaceutical company, received FDA approval for GAMMAGARD LIQUID as an IVIG therapy for adults with CIDP. This approval allows its use as an induction therapy, beginning with an initial dose followed by maintenance doses to support long-term disease management and enhance neuromuscular function.
What Are the Top Market Players Propelling the Growth of theChronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
Order Your Report Now For A Swift Delivery:
Which Primary Segments of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Are Driving Growth and Industry Transformations?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=21144&type=smp
Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?# Market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market 2025, By The Business Research Company:
Pediatric Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pediatric-vaccine-global-market-report
Chickenpox Vaccine Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report
Stem Cell/Cord Blood Banking Global Market Report 2025
https://thebusinessresearchcompany.com/report/stem-cell-cord-blood-banking-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
